Trial Profile
Subcutaneous vs intravenous bortezomib in previously untreated patients with multiple myeloma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Sep 2014
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Bortezomib (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 26 Sep 2014 New trial record